MEF2D and neuroendocrine carcinoma: This screen successfully identified small molecules that positively or negatively alter the splicing levels of the screen-assayed Mef2d microexon, as well as of a broader programme of neural microexons that is disrupted in ASD and activated in neuroendocrine cancers.